This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Enabling Digital Screening for Pancreatic Cancer using Artificial Intelligence Analysis of Disease Trajectories
-
A Phase II Randomized Blinded Trial of AI-Assisted Versus Manual Contouring by New Learners in Ultrasound-Based Prostate HDR Brachytherapy
-
CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer
Amgad Muneer, et al.. Journal for ImmunoTherapy of Cancer, 2026.
DOI: 10.1136/jitc-2026-015014
Weekly News Brief: October 12–16, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of October 12–16, 2026.
This week’s brief covers a transformer model that flags pancreatic cancer risk 5 years early, AI contouring that brings trainee prostate brachytherapy contours closer to attending quality, and a CT-based foundation model that predicts immunotherapy pneumonitis risk in lung cancer.
To learn more about predicting pancreatic cancer risk, read "Transformer-Based AI Model Identifies Pancreatic Cancer Risk Years Before Diagnosis," or see the abstract.
For more information on a study of AI-assisted contouring, read "AI Auto-Segmentation Narrows the Gap Between Trainee and Attending Contours in Prostate Brachytherapy," or see the abstract.
To learn more about CIPHER, read "Foundation Model Predicts ICI-Induced Pneumonitis Risk in NSCLC," or see the source report in the Journal for ImmunoTherapy of Cancer.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.